嘉必優(688089.SH)擬投資9900萬元參與設立產業投資基金 持股佔比49.5%
格隆匯7月30日丨嘉必優(688089.SH)公佈,為滿足公司戰略發展需要,公司與武漢鼎石匯澤投資管理有限公司、湖北振華化學股份有限公司合作發起設立蘇州鼎石匯澤生物產業投資基金合夥企業(有限合夥),投資於生物技術領域的產業項目。
公司已於2020年7月30日與合作方簽署了《蘇州鼎石匯澤生物產業投資基金合夥企業(有限合夥)合夥協議》。本次基金規模2億元,其中,公司作為有限合夥人以自有資金出資9900萬元,佔比49.5%,出資方式為貨幣出資。
通過項目直接投資或投資於子基金等方式,主要投向生物技術領域的產業創新項目,包括但不限於人類營養、動物營養、醫療保健、生物醫藥、食品飲料、日化洗護、生物基材料、生物環保等領域的生物技術、產品服務及應用解決方案等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.